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ABSTRACT 
 
 Florida is one of two states that do not allow ARNPs to prescribe controlled substances. 
The Florida Legislature has expressed concern regarding the safety of ARNPs prescribing 
controlled substances. The purpose of this study was to compare malpractice rates of ARNPs and 
physicians in states with and without controlled substance prescribing.  
The design was a direct comparison of malpractice rates in states with and without ARNP 
controlled substance prescriptive authority.  Comparison of malpractice claims was made 
between physicians (MDs and DOs collectively) and ARNPs in the United States and by state 
ARNP prescribing authority. Comparison of malpractice claims was also made between Florida 
and states that were demographically similar.  
The results showed that ARNPs have significantly less malpractice than physicians in the 
United States. In addition, there were no significant differences in malpractice, whether or not 
the ARNP was allowed to prescribe controlled substances. Finally, ARNPs working in states that 
are demographically similar to Florida, but allowed to prescribe controlled substances had no 
significant increase in malpractice.  
This study showed that there is no increase in malpractice rates in states where ARNPs 
prescribe controlled substances, either fully or partially, supporting the hypothesis.       
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 CHAPTER 1: INTRODUCTION/SCOPE OF THE PROBLEM 
 
Nurse practitioners have been in clinical practice for over 40 years and have experienced 
expanded privileges to their practice.  A total of 48 states now allow Advanced Registered Nurse 
Practitioners (ARNPs) at least partial controlled substance prescribing privileges and 34 states 
grant ARNPs full prescriptive privileges for Class II-V controlled substances without restrictions 
(Byrne, 2008).  Full prescriptive privileges have promoted practice autonomy for ARNPs and 
access to care and services for clients.  While the advances in prescriptive practices have 
occurred in 48 states, the State of Florida has not permitted its ARNPs to practice at their full 
potential (Miller, 2005).   The purpose of this study is to compare malpractice rates of ARNPs 
and physicians in states with and without controlled substance prescribing. 
 
Definition of Terms 
 For the purposes of this study, each term will be defined by their conceptual and 
operational meanings.  Conceptual definitions express the idea of the term (Rogers & Knafl, 
2000).   Walker and Avant’s meaning of an operational definition (as cited in Rogers, 2000) are 
ways in which the concept can be measured.  
Malpractice 
Conceptual: Any act or omission by a provider during patient treatment that deviates from 
accepted standards of care and causes injury to a patient (Bal, 2009). 
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Operational: Physician or ARNP who have committed an error and declared responsible for the 
error, such as delay of appropriate care. 
Malpractice Rate 
Conceptual: Number of occurrences that providers have been accused of malpractice.  
Operational: Rates listed in the National Practitioner Data Bank (NPDB) which indicates the 
number of malpractice payment reports by state. 
Incident  
Conceptual: Events in healthcare which may cause unanticipated harm to a patient (Farlex, 
2009).   
Operational: Inappropriate medication prescribed, illegal dispensing of controlled substances, or 
an incident which did not involve medications, such as an incorrect or missed diagnosis.  
Controlled Substances 
Conceptual: Those medications which have a certain degree of addictive properties and are 
regulated by the DEA (Drug Enforcement Administration). 
Operational: Medications such as narcotics, barbiturates, and sedatives. 
Full Prescriptive Authority 
Conceptual:  ARNPs are allowed by law to prescribe Class II-V controlled substances 
independent of physician involvement. Physicians may be involved in terms of collaborative or 
supervisory practice in general terms.  
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Operational: Patient requires a Class II medication such as Methylphenidate for Attention 
Deficit Hyperactivity Disorder and the ARNP prescribes for the patient without involving the 
physician.  
Partial Prescriptive Authority 
Conceptual: ARNPs are limited by law in prescribing Class II-V controlled substances. This may 
be a limitation by class, indication, or quantity.  
Operational: The ARNP is allowed to prescribe only a seven-day supply of a Class II 
medication. Patients who require controlled substances may need a physician involved in their 
care.  
No Prescriptive Authority 
Conceptual: ARNPs are not allowed to prescribe controlled substances medications.  
Operational: Patients who require medications such as a medication for sleep must have a 
physician involved in their care.  
Supervising Physician  
Conceptual: physician (Medical Doctor or Doctor of Osteopathic Medicine) that has a 
collaborative protocol agreement with an ARNP (Florida Department of Professional Regulation 
Board of Nursing, 1990). 
Operational: A physician that accepts responsibility to oversee an ARNPs practice.  
Controlled substances are grouped into the following five classes by the Drug 
Enforcement Administration (DEA) (Drug Enforcement Administration, 2008). Class I 
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prescriptions are highly addictive and highly abusive substances, and are illegal to prescribe in 
the United States (U.S.). Class II prescriptions are those which have a high potential for abuse 
and physical dependence. Included in this group are prescriptions for Attention Deficit 
Hyperactivity Disorder and severe pain. Class III prescriptions can cause moderate or low 
physical dependence or high psychological dependence. Class III medications are generally 
prescribed for moderate to severe acute pain. Class IV prescriptions have a low abuse potential 
and limited potential for physical or psychological dependence. Class IV medications are 
generally prescribed for sleep and anxiety. Class V medications have a low abuse potential, and 
may or may not require a prescription. Class V medications include certain cough medicines, 
seizure medicines, and anti-diarrheal medications.   
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CHAPTER 2: SYNTHESIS OF THE RESEARCH EVIDENCE 
 
In 1977, the first proposal for a Scope of Practice for Advanced Practice Nurses in 
Florida was created by a Joint Committee of members from the Florida Department of Health 
Boards of Medicine and Nursing (Lumpkin, 2004).  In 1979, the Advanced Registered Nurse 
Practitioner (ARNP) was defined and added to the Florida Nurse Practice Act. Included in the act 
was the requirement that each ARNP would have a supervising physician who would also be 
legally responsible for the care and treatment provided by the ARNP. This supervising physician 
would establish protocols with the ARNP that delineate the scope of practice with the 
supervising physician. The protocols are then submitted to the Boards of Nursing and Medicine, 
with bi-annual updates (Florida Department of Professional Regulation Board of Nursing, 1990). 
Florida was one of the first states to pass legislation to regulate advanced nursing practice. In 
1987, the Joint Committee again convened and authorized ARNPs to prescribe non-controlled 
substances (Lumpkin, 2004). 
By 1988, ARNPs were working with their supervising physicians to update protocols to 
include non-controlled substance medications.  In 1995, an ARNP task force was assembled to 
develop a bill which would allow nurse practitioners the ability to prescribe controlled substance 
medications.  The bill was opposed by both the Florida Pharmacy Association and the Florida 
Medical Association and was defeated (Lumpkin, 2004).  There were several issues which   
contributed to the bill’s defeat.  One of the issues identified was the allowance of nurse 
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practitioners to gain ARNP licensure through a certificate without additional education. In 
addition, there was a nursing movement nationally to standardize basic as well as advanced 
educational preparation. The Florida Nurses Association (FNA) began working on minimum 
education requirements to facilitate a future bill for advancing ARNP scope of practice. In 1996 
a law was passed that changed the minimum education requirement of ARNPs to be a master’s 
degree in advanced practice nursing beginning in 1998 (Lumpkin, 2004).  
In 1997, the Florida Legislature mandated the creation of a task force appointed by the 
Agency for Healthcare Administration to include pharmacists, nurses, physicians and doctors of 
osteopathy, as well as a Florida Hospital Association representative. The Prescribing of 
Controlled Substances task force was developed to evaluate the risk and benefits of ARNPs 
prescribing controlled substance medications in Florida.  Their study concluded that ARNPs are 
safe to prescribe controlled substance medications (Prescribing of Controlled Substances Task 
Force, 1997). This conclusion was based on the findings that the potential for harm to patients or 
increase in substance abuse by ARNPs was very limited. In addition, trends of malpractice 
payments indicated that in the three years following the Drug Enforcement Agency (DEA) 
authorization of “mid-level providers” [sic] to be granted DEA numbers, there was a 5% increase 
in malpractice claim awards payments for physicians but a 22% decrease in malpractice claim 
awards payments for ARNPs (Prescribing of Controlled Substances Task Force, 1997). There 
was dissent, however among the physicians in the group, who wrote a Minority Report, 
expressing four primary concerns.  The first concern was that there were no studies available 
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regarding the safety of controlled substance prescribing by ARNPs.  The second concern was 
that many states had limitations on controlled substance medication prescribing.  The third 
concern was that education was lacking in specific pharmacology training.  The fourth and final 
concern was that to have ARNPs prescribing controlled substance medications would result in an 
increase in the liability exposure for the supervising physician.  At the time of the 1997 study, 32 
of 50 states had passed legislation to allow ARNPs to prescribe at least some form of controlled 
medications.  Unfortunately, between 1997 and 2001, the Florida Legislature continued to 
oppose allowing ARNPs to prescribe controlled substance medications (Lumpkin, 2004).  As 
recently as December, 2008, the Florida Senate’s Committee on Health Regulation met to hear 
Interim Report 2009-117 which was a report reviewing ARNP prescriptive authority (The 
Florida Senate, 2008).  The Senate professional staff recommended extending controlled 
substance prescribing authority to Florida licensed ARNPs who have attained national 
certification.  One senator again brought up the safety of ARNPs prescribing controlled 
substances and directly asked about malpractice rates in other states that allow ARNPs this 
authority.  No study to-date had occurred. Of the seven senators present, Senators Michael 
Bennett, Dennis Jones and Minority Leader Alfred Lawson were in favor of moving the bill 
forward, Senator Dave Aronberg was in favor of allowing ARNPs to prescribe class III-V, 
Senators Eleanor Sobel and Thad Altman were opposed, questioning whether there were any 
studies on the safety of ARNPs prescribing controlled substances, and Senators Andy Gardiner 
and Don Gaetz were silent on the matter.  Since consensus could not be reached, the bill was put 
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forth by Senators Bennett and Jones, but the bill was never heard on the floor (Senate Committee 
on Health Regulation, 2008). Then in the 2010 legislative session the head of the House of 
Representatives Health Care Regulation Policy Committee, Representative Nick Thompson 
stated that he would not accept any scope of practice bills this session (Small, 2010).  
Patients, ARNPs, and physicians in the state of Florida are faced with many challenges as 
a direct result of ARNPs not having full prescriptive authority.  Challenges include lost 
productivity of the ARNP waiting for a physician to write a prescription, delay of care for the 
patient, lost productivity of the physician to leave his own patient to care for the ARNPs 
patient’s needs, and increased liability for the physicians to write prescriptions for patients with 
whom they are less familiar (Kaplan & Brown, 2004).  If the physician is not available, the 
patient must arrange a second appointment specifically with the physician to obtain the 
appropriate medication. The cost for a patient to make a return visit impacts the patient by 
increased time taken from other activities and delay of treatment. A return visit also impacts the 
insurance providers, as there will be a second office visit charge (Kaplan, 2004).  Patients in 
rural areas are most vulnerable to these types of consequences, due to physician shortages 
(Ricketts & Holmes, 2007; Hill, 2008; Millson, 2008). ARNP managed clinics in rural and 
underserved areas cannot provide patients appropriate services without the ability to prescribe 
the medications needed for treatment of the condition.  ARNPs also have obstacles when 
practicing in specialty practices such as palliative care and pain management, negatively 
impacting the patient’s quality of life and comfort. In addition, ARNPs prescribing trends are not 
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accurately reflected when a physician must write a prescription for the ARNP’s patient. For 
example, an ARNP’s patient requires a medication for anxiety prior to a procedure (such as a 
Magnetic Resonance Imaging [MRI]). The protocol for the office is lorazepam, a Class IV 
controlled substance. The physician must write the order, making the number of controlled 
substances for his/her patient population falsely high, while the ARNP’s record shows none.  
Regulations which limit the ARNPs scope of practice, including prescribing controlled 
substances, reduce their ability to meet patient’s health care needs (Lugo, O’Grady, Hodnicki, & 
Hanson, 2007). 
The Florida Legislature has expressed concern regarding the safety of ARNPs being 
given the privilege of prescribing controlled substances.  This is in direct opposition to the report 
written by the professional staff of the Committee on Health Regulation, which stated that 
ARNPs pose no greater risk to patients by prescribing more inappropriately than other providers 
who have this authorization. Two Senators expressed their own concerns. One concern was 
increased prescription drug abuse in Florida and the other is that there is no evidence on 
malpractice incidence in controlled substance prescribing (The Florida Senate, 2008). A recent 
study evaluated the extent of illicit drug use in the U.S. Drugs included categories of both illegal 
substances (heroin, marijuana, and cocaine) and prescription substances used for non-medical 
purposes (narcotic pain relievers, tranquilizers, sedatives and stimulants). The Table I shows the 
rate of illicit drug use in 2007 comparing U.S. regions (Substance Abuse and Mental Health 
Service Administration, 2008).  
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Table 1: Illicit Drug Use in Persons over 12 
U.S. Region Percent of persons older than age 12 using illicit 
drugs 
   
West 9.3% 
Midwest 7.9% 
Northeast 7.6% 
South 7.4% 
  
Substance Abuse and Mental Health Service Administration, 2008 
  
There have been over 50 studies which have evaluated outcomes, patient satisfaction, and 
differences in practice patterns between ARNPs and physicians, but in no study has malpractice, 
negative licensure actions, civil judgments, or criminal convictions data been compared for 
physicians and ARNPs (Action for Sick Children, 1999; Chumbler, Geller, & Weier, 2000; 
Shell, 2001; Jacobs, 2005; Cipher, Hooker, & Guerra, 2006). Therefore this study seeks to 
address whether the actual difference in the scope of practice of controlled substance prescribing 
of ARNPs affects malpractice judgments, negative licensure actions, civil judgments, and 
criminal convictions.  
   Cumulative Index to Nursing and Allied Health Literature (CINAHL) and MEDLINE 
databases were used to complete the literature review for this study. Initial search terms included 
Prescribing and Malpractice and ARNP. This produced no results.  The second search included 
Prescribing Controlled Substances and ARNP or Advanced Practice Nurse. Restrictions were 
then placed to include English only. This search produced a yield of 2,167 articles. The third 
search included the terms Nurse Practitioner and Prescribing or Malpractice. This produced a 
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yield of 137 articles. There were no peer reviewed data-based research articles which compared 
the prevalence of malpractice between ARNPs and physicians. Included in the literature review 
were those articles which evaluated the safety of care provided by ARNPs in comparison to 
physicians, articles identifying barriers to ARNP practice, including controlled substance 
prescribing and articles assessing whether care provided by ARNPs is cost-effective.  
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Table 2: Controlled Substance Prescribing Literature Review  
 CINAHL and MEDLINE Database 
Key Words/Limits Articles 
Prescribing, ARNP, Advanced Practice Nurse; Limitations: English Only; 
No Limit to Dates of Articles  
 
2167  
 
Prescribing, ARNP, Advanced Practice Nurse. Date Limits set from 2006 to 
2008 
 
1,650 
Prescribing Controlled Substances, ARNP, Advanced Practice Nurse. Date Limits 
2006-2008 
 
Nurse Practitioner, Prescribing or Malpractice 
 
940 
 
 
137 
    
 
   
There have been over 50 studies comparing care and treatment of patients between 
ARNPs and Physicians. These studies consistently support that care and outcomes are similar 
between the providers (Haider, 2008; Horrocks, Anderson & Salisbury, 2002; Brown and 
Grimes, 1995). In a review of prescriptive practices of psychiatrists and psychiatric nurse 
practitioners, there were no significant differences in patient adherence to medications (Jacobs, 
2005). Significant differences were found in physician’s utilization of more second generation 
antidepressants and anxiolytics than the ARNPs who provided more first generation and generic 
medications when appropriate. 
 In terms of time spent with the patients, the ARNPs had increased face-to-face visit time 
with patients and they used more integrated therapy, such as biofeedback and psychotherapy 
(Jacobs, 2005).  One study found that patients perceived nurses to be more approachable when 
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medications were needed and that since the ARNP could prescribe the medicine, treatment could 
be started sooner rather than waiting for a physician to prescribe. Specifically, patients stated that 
they had established a relationship with their nurse, and felt that the ARNP knew more about 
their condition than a physician who didn’t know their background (Luker, 1998). ARNPs and 
physicians also experience similar difficulties ensuring patient safety in prescribing whether 
prescriptive authority is limited or full, such as patient expectations regarding medication, self 
adjusting medication and abuse (Jacobs, 2005). Since the ARNP has been shown to provide 
patients with more education regarding care and treatment, the risk should not increase, but be 
equivalent or possibly decrease (Little, 2001).  
In a study by Cipher (2006), there were increases in the amount of controlled substance 
prescribing among ARNPs from 1996-2002, compared to the seven years prior, however over 
the time of the study more and more states were passing laws allowing ARNPs to either 
prescribe controlled substances, or expand the degree to which they were allowed to prescribe 
controlled substances.   
  The Florida Medical Association in its Minority Report to the Florida Legislature 
brought up the concern of increased liability exposure to the supervising physician if ARNPs are 
allowed to prescribe controlled substances (The Joint Committee Task Force, 1997). The term 
“supervising physician” can allow a lawsuit to expand, and even those with appropriate practice 
can receive a lawsuit, but if the physician has never seen the patient, nor been asked his/her 
advice, then the physician as a defendant in the suit would be most likely dropped (Buppert, 
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2001). The case, however, becomes more complicated with current restrictions on prescribing for 
ARNPs. Consider that the ARNP’s patient requires a controlled medication, such as a refill on a 
Class II drug for Attention Deficit Hyperactivity Disorder (ADHD). The nurse practitioner must 
obtain the controlled substance prescription from the physician and give it to the patient. The 
physician did not evaluate the patient and yet the physician’s name must be on the prescription 
for the medication. This leads to not only increased liability for the physician who is now 
responsible for the outcome, but inappropriate tracking of prescribing trends in all states with 
limitations (Lebo, 2007). Poor outcomes alone, however, are not the only reason that persons 
bring about a lawsuit, but lapse in communication following the occurrence is a major issue 
(Baum & Dowling, 2009). Communication is one area that nurse practitioners have improved 
skills compared to physicians. In a meta-analysis by Haider, surveys indicated patients preferred 
ARNPs due to the increased time spent in communication with the patient (Shum, Humphreys, 
Wheeler, Cochrane, Skoda, & Clement, 2000; Haider, 2007). In the same meta-analysis, mothers 
of sick children expressed that family physicians made them feel anxious, and gave them vague 
instructions for care (Haider, 2007, Action for Sick Children, 1999). More recently, a nurse 
practitioner managed cardiac clinic at the Cleveland Clinic was designed to address the needs of 
heart patients in terms of improving health outcomes as well as preventive care. Surveys were 
conducted monthly to assess the quality of the program as this was originally managed by 
physicians. After one year, the clinic was found to be cost-effective, had improved patient 
satisfaction scores in the areas of communication and spending enough time with the patient, and 
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improved outcomes including significant reductions in total cholesterol, triglycerides, high-
density lipoprotein, low-density lipoprotein, blood pressure, and C-reactive protein (Gambino, 
Planavsky, & Gaudette,  2009). Studies consistently show that ARNPs can effectively reduce 
healthcare costs while maintaining quality, improving communication and improving outcomes.  
 In Barriers to Autonomous Practice, Kaplan (2004) studied specific barriers to 
prescriptive authority with controlled substances II-V and grouped ARNPs into those with full 
authority and those without authority in the State of Washington. The study questioned the 
ARNPs before the law authorizing prescriptive authority for Class II-IV was in place and again 
soon after the law was enacted. Findings revealed that the ARNPs primary reason for not 
pursuing DEA registration and prescriptive authority were lack of expertise in prescribing 
specific Schedule II-IV drugs. The author continued to follow the same ARNPs over a two year 
period and found that by year two, two-thirds of the ARNPs had obtained DEA licenses and 
were prescribing controlled substances. One premise as to why the ARNP did not wish to 
prescribe controlled substances reported a concern regarding patients with drug-seeking behavior 
(Kaplan, 2004). These findings both support the requirement for pharmacology education for 
ARNPs with regards to controlled substance prescribing (Kaplan, 2004).  
State limitations have also imposed barriers to practice, limiting the ARNP’s ability to 
practice to their fullest capacity (Pan, Straub & Geller, 1997). Rankings of states related to 
ARNP autonomous practice (including prescriptive authority) were published to show the 
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disparity of scope, despite standardized training. In this study, Florida ranked 49th out of 51 
states including the District of Columbia (Lugo, 2007, Phillips, 2009).  
Recently, several national advanced practice nursing groups have united to create a 
Consensus Model for Advanced Practice Registered Nurse (APRN) regulations: Licensure, 
Accreditation, Certification and Education (Trossman, 2008). This document was created and 
endorsed by several advanced practice specialist or specialty groups, including nurse-midwives, 
clinical nurse specialists, and nurse practitioners to standardize the education and regulatory 
processes for APRN practice and promote APRNs independent function, including prescriptive 
authority (Trossman, 2008).  
Cost savings is another advantage to allowing ARNPs full prescriptive authority. In a 
recent cost-benefit analysis, a net benefit of $32 million dollars in the state of Florida per year 
was estimated (Chandler, 2007). Cost estimates included time for the practitioner to find the 
physician, the physician to stop his patient flow to prescribe the medication, and those instances 
where a second office visit would be required, should the physician not be in the office at the 
time (Chandler, 2007). Nurse practitioner managed clinics (NMCs) are also a way to improve the 
cost of healthcare. Coddington & Sands (2008) conducted a meta-analysis describing five NMCs 
as having significant impact on reduced emergency department, urgent care centers and 
hospitalization visits. This is enhanced by providing preventive services to persons who could 
otherwise not afford treatment. In one study, Schroeder (1993) estimated over $750,000 in 
savings was found by ARNP care in reducing the number of HIV patients hospitalizations and 
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the following year, over one million dollars savings was realized. Another study evaluated a  
NMC, and found that some months after opening, the local emergency department found that the 
NMC’s clients were only making up 0.3% of overall visits (Helvie, 1999). A thirteen million 
dollar savings occurred in another hospital following a NMC opening, by a 25% reduction in 
emergency department visits (Smith-Campbell, 2005).   
 In conclusion, there are over 50 studies which compare care and treatment between 
ARNPs and Physicians but none which specifically look at comparing the prevalence of 
malpractice claims in states with and without ARNP controlled substance prescribing privileges 
regulation.    
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CHAPTER 3: PROJECT IMPLEMENTATION 
 
The purpose of this study was to identify any difference in malpractice rates among 
ARNPs and physicians in states with either full or partial controlled substance prescriptive 
authority. The data was reported from the National Practitioner Data Bank as cumulative 
malpractice claims for each state (Pearson, 2010). Specific data regarding malpractice rates 
secondary to controlled substance prescribing was not available. The physician’s rates were 
calculated as Medical Doctor (MD) malpractice rates and Doctor of Osteopathic Medicine (DO) 
malpractice rates combined. This design was chosen to provide a direct comparison of 
malpractice rates in states with and without ARNP controlled substance prescriptive authority. 
Various studies have been conducted that compare outcomes, practice patterns, and cost 
effectiveness of ARNPs utilizing a full scope of practice, but no studies have specifically looked 
at prescriptive authority and malpractice rates.  
The population for this project included all ARNPs and physicians in all of the U.S. and 
the District of Columbia. Data regarding total population for each classification was derived 
from the Pearson Report (Pearson, 2010). Rates of malpractice were obtained from the National 
Practitioner Data Bank Summary Report and the National Practitioner Data Bank 2006 Annual 
Report (Pearson, 2010). Information regarding adverse action reports, civil judgments, and 
criminal conviction reports was obtained from the Healthcare Integrity and Protection Data Bank 
(Pearson, 2010). For this study, several sources were evaluated for the most accurate 
19 
 
determination of malpractice data. The closest data set to reflect malpractice data in the United 
States is the National Practitioner Data Bank. This information, however, is not complete in 
itself.  Actions restricting clinical privileges and professional society membership sanctions are 
mandatorily reported for physicians and dentists but are voluntarily reported for other providers 
to include ARNPs (National Practitioner Data Bank, 2006). Malpractice reports are also skewed 
in that some providers may have had two or more malpractice suits which inappropriately 
worsen rates for the entire provider group. In addition, the National Practitioner Data Bank 
reports cumulative data from 1990-2008, and not annual rates. Finally, states have granted 
controlled substance prescriptive authority to ARNPs in various years, which may make some 
states malpractice rates with earlier legislation related to controlled substance prescribing more 
accurate than those states that have changed prescriptive authority in more recent years. 
Therefore, other sources for data were included and are presented in the following table. 
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Table 3: Sources for Data Collection 
Agency  Data to be Collected 
Federal Drug Enforcement Agency (DEA) Case reports of DEA intervention against providers who 
have been sanctioned in some way related to controlled 
substance prescribing. 
 
Health Integrity Protection Data Bank Number of reports concerning individuals by professional 
type and by Federal Licensure and DEA Action 
 
Kaiser Foundation State health facts concerning number of practitioners in 
each state and demographic characteristics of the 
professions in the state.  
 
National Practitioner Data Bank Number of malpractice cases by provider type and state 
which resulted in payment.    
 
Pearson Report Overall prevalence of malpractice rates in each state by 
professional type.  
  
    
    
  
 
Design 
 This study was conducted as a secondary analysis of collected data regarding malpractice 
rates among ARNPs and physicians. The design was chosen after an extensive search of other 
sources for specific information regarding malpractice related to controlled substance 
prescribing. The Drug Enforcement Administration tracks and presents specific cases of misuse 
of controlled substances rather than aggregate data. The Health Integrity Protection Data Bank 
tracks the number of adverse events, criminal convictions and civil judgments against 
practitioners, but is only mandated for MDs and DOs and voluntarily reported by ARNPS. There 
was also investigation of insurance companies that carried malpractice insurance for physicians 
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and ARNPs to assess whether controlled substance prescribing increased the risk, and therefore 
the rate of insurance, versus a provider that did not prescribe controlled substances. It was 
discovered, however, that controlled substance prescribing was only a small part of a larger 
complex formulation in determining annual malpractice insurance rates. No source was found 
that monitored malpractice as it relates to controlled substance prescribing by state. The closest 
source that monitored overall malpractice by state was the National Practitioner Data Bank.  
Human Subjects 
There was no risk to human subjects. All of the data collected was public domain and has 
been reviewed by other methods to describe specific trends. The University of Central Florida 
Institutional Review Board reviewed this study and determined that the proposed study was not 
human research and thereby exempt from IRB review (see Appendix). 
Data Analysis  
Data was analyzed using the SPSS Database system. Frequency distributions were 
performed for each of the research questions. 
  In this study, each state was listed in the data spreadsheet. All 50 states including the 
District of Columbia were coded according to the level of ARNP controlled substance 
prescribing regulations: full, partial, or none. Each state then had listed the total number of 
ARNPs practicing in the state as well as the total number of MD’s, DO’s and combined 
physicians practicing in the state. Finally, malpractice rate by provider type (ARNP, MD, and 
DO) for each state was analyzed.  
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The research questions for this study included the following:  
• What was the rate of malpractice claims by state against ARNPs compared to physicians 
in the U.S.?   
• What was the rate of malpractice claims against ARNPs compared to physicians in states 
in which ARNPs have full controlled substance prescribing privileges?  
• What was the rate of malpractice claims against ARNPs compared to physicians in states 
in which ARNPs have partial controlled substance prescribing privileges?  
• What was the rate of malpractice claims against ARNPs compared to physicians in states 
in which ARNPs do not have controlled substance prescribing privileges?  
• Was there a difference in the rate of malpractice among ARNPs based on prescriptive 
authority? 
• Was there a difference in ARNP malpractice rates in Florida compared to states 
demographically similar to Florida but allowing controlled substance prescribing?  
   Statistical evaluation included frequency distributions, mean distribution, one-sample t-
test, Wilcoxon Signed Ranks test, and the Kruskal-Wallis test. Graphic representation of the data 
was also utilized. Independent variables included the number of ARNPs nationally and in each 
state, the number of physicians nationally and in each state, and ARNP prescribing privileges. 
Dependent variables included the rate of malpractice per 1000 per discipline, and the rate of 
malpractice in each state. States were then coded as determined by the level of autonomy nurse 
practitioners have to prescribe controlled substances (full prescribing, partial prescribing and no 
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prescribing).  The hypothesis was that there was no statistically significant difference in the 
malpractice rates of ARNPs and physicians in states with and without controlled substance 
prescribing.    
 There are a number of limitations inherent in this study. Data collected regarding 
malpractice was not equal among providers. There were only two professions that required 
mandatory reporting for malpractice incidents with the National Practitioner Data Bank, 
physicians and dentists. In addition, malpractice rates do not specifically represent malpractice 
related to controlled substance prescribing.  Malpractice payment reports also do not distinguish 
those providers who have had one malpractice claim or several. This can affect the overall rate of 
malpractice as well. The available data can only be interpreted as to whether there is evidence 
that ARNPs in states with controlled substance prescribing have overall significantly more 
malpractice judgments against them compared to ARNPs in states without controlled substance 
prescribing.    
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CHAPTER 4: RESULTS 
 
 In this chapter, the findings of the data analysis are presented. The sample for the study 
included data for the 50 United States and the District of Columbia. Data collected from each 
state included numbers ARNPs, DOs and MDs by state, malpractice rates by state, adverse 
actions, civil judgments and criminal convictions reports, and level of state ARNP prescribing 
privileges. For malpractice rates, data was analyzed by malpractice rate per 1000 providers for 
each set and then compared. Comparison results to address the research questions were as 
follows:  
 
Question 1: What was the malpractice rate for ARNPs compared to physicians in the United 
States?   
There were 156,958 ARNPs in the U.S, (mean [M] = 3,078 per state; Median [Mdn] = 2,319 per 
state). The average or mean rate of malpractice for every 1000 ARNPs was 6.29.  There were 
over 978,672 physicians in the U.S (M = 19,190 per state, Mdn = 11,829 per state).   The average 
or mean rate of malpractice for every 1000 physicians was 249.75. The results of the Wilcoxon 
signed rank test indicated that nurse practitioners (Mdn = 5.28) have statistically significant 
lower malpractice rates than physicians (Mdn = 247.75) (p<.001). 
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 Figure 1. Comparison of Malpractice Rates for Physicians and ARNPs  
 
Question 2:  What was the rate of malpractice claims against ARNPs compared to physicians 
in states in which ARNPs have full controlled substance prescribing privileges? 
There were 34 states including the District of Columbia that allow ARNPs full prescriptive 
authority. The number of ARNPs in states with full prescriptive authority totaled 93,083. In the 
same states there were 565 malpractice claims. The average or mean rate of malpractice for 
every 1000 ARNPs in states with full prescriptive authority was 7.00. The number of physicians 
in states where ARNPs have full prescriptive authority was 552,461. In those same states there 
were 133,995 malpractice claims against physicians. The average or mean rate of physician 
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malpractice in states with ARNP full prescriptive authority for every 1000 physicians was 
234.97. The results of the Wilcoxon signed rank test indicated that malpractice rates against 
ARNPs in states with full prescriptive authority (Mdn = 6.21) have statistically significant lower 
malpractice rates than physicians (Mdn = 222.63) in those states (p<.001).  
 
Question 3:  What is the rate of malpractice claims against ARNPs compared to physicians in 
states in which ARNPs have partial controlled substance prescribing privileges? 
There are 15 states that allow ARNPs partial prescriptive authority. The number of ARNPs in 
states with partial prescriptive authority was 50,804. The average or mean rate of malpractice for 
every 1000 ARNPs in states with partial prescriptive authority was 4.48. The number of 
physicians in states where ARNPs have partial prescriptive authority was 356,136. In those same 
states there were 107,439 malpractice claims against physicians. The average or mean rate of 
physician malpractice in states where ARNPs have partial prescriptive authority for every 1000 
physicians was 288.47. The results of the Wilcoxon signed rank test indicated that malpractice 
rates against ARNPs in states with partial prescriptive authority (Mdn = 3.73) have statistically 
significant lower malpractice rates than physicians (Mdn = 262.74) in those states (p<.001).  
 
Question 4:  What is the rate of malpractice claims against ARNPs compared to physicians in 
states in which ARNPs do not have controlled substance prescribing privileges? 
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There are two states that did not allow controlled substance prescriptive authority. The number 
of ARNPs in states that do not allow controlled substance prescriptive authority was 13,071. The 
average or mean malpractice rate for every 1000 ARNPs in states that do not have controlled 
substance prescriptive authority was 7.94.  There were 70,075 physicians in states in which 
ARNPs do not have controlled substance prescriptive authority. The average or mean 
malpractice rate for every 1000 physicians in states where ARNPs do not have controlled 
substance prescriptive authority was 210.46. The results indicate that ARNPs have lower 
malpractice rates than physicians in states that do not allow ARNP controlled substance 
prescribing.  
 
Question 5:  Is there a difference in the rate of malpractice among ARNPs based on 
prescriptive authority?     
Statistical analysis was performed using the Kruskal-Wallis test to evaluate significant 
differences in malpractice rates for ARNPs in states with full, partial and no prescriptive 
authority. The average or mean malpractice rate for every 1000 ARNPs in states with full 
prescriptive authority was 7.00.  The average or mean malpractice rate for every 1000 ARNPs in 
states with partial prescriptive authority was 4.48. The average or mean malpractice rate for 
every 1000 ARNPs in states without controlled substance prescriptive authority was 7.94. The 
results of the Krukal-Wallis one-way ANOVA by ranks indicated that there were no statistically 
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significant differences among the three prescribing privilege categories (χ²K-W=4.304, df=2, 
p=.116). 
 
Table 4: Summary of Malpractice Rate/1000 by ARNP Prescribing Privileges  
Controlled Substance  
Prescribing Authority 
Number of 
States (n) 
Number of 
ARNPs  
Mean/ 
Median  
 Per State 
Number of 
Physicians 
Mean/ Median 
Per State  
Full Prescriptive 
Authority 
 
34 93,083 7.00/6.21 552,461 234.97/222.63 
Partial Prescriptive 
Authority  
 
15 50,804 4.48/3.73 356,136 288.47/262.74 
No Prescriptive 
Authority 
2 13,071 7.94/7.94 70,075 210.46/210.46 
      
 
 Question 6:  Was there a difference in ARNP malpractice rates in Florida compared to states 
demographically similar to Florida but that allow ARNP controlled substance prescribing?  
Two criteria were used to compare states that were demographically similar to Florida, the state 
population size and number of uninsured residents. From this criteria, three states were found 
comparable to Florida; Illinois, New York, and Texas. The following table provides a 
comparison of the states, controlled substance prescribing authority and individual malpractice 
rates.  
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Table 5: ARNP Malpractice Rate Comparisons to Florida  
State 
 
Population Size Number of 
State 
Uninsured 
Prescriptive Authority ARNP 
Malpractice 
Rate/1000 
Florida 
 
18,029,897 3,738,230 No Controlled 
Substance Prescribing 
 
14.24 
Illinois 12,642,143 1,737,876 Partial Controlled 
Substance Prescribing 
 
 3.78 
New York 19,046,037 2,590,364 Full Controlled 
Substance Prescribing 
 
 5.28 
Texas 23,406,068 5,832,884 Partial Controlled 
Substance Prescribing 
 
 8.47 
        
 
 Table 5 indicates that ARNPs with full and partial prescribing authority in states that are 
demographically similar have lower malpractice rates compared to Florida which does not allow 
controlled substance prescribing.   
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CHAPTER 5: DISCUSSION 
 
 ARNPs have been providing cost-effective, comparable care for over forty years. This 
study was completed to evaluate malpractice rates in states where ARNPs have full prescriptive 
authority to those ARNPs with limited or no prescriptive authority to demonstrate that there was 
no increased risk of malpractice to the ARNP or the physician when allowing ARNPs to 
prescribe controlled substances.  
 The average or mean rate of malpractice among ARNPs and physicians varied by state 
and by discipline. Average or mean malpractice rates for every 1000 physicians varied between 
94.27 (Alabama) and 486.72 (Montana) with Mdn = 247.75. Malpractice rates for every 1000 
ARNPs varied between zero (Hawaii and Vermont) and 26.56 (New Mexico) with Mdn = 5.28. 
This data was included to provide a baseline for the results of the questions that followed. There 
are several possible explanations for the variance. Laws in each state regarding malpractice were 
not evaluated for this study, but could have an impact on the overall rate. ARNPs have not been 
in practice as long as physicians and do not typically provide care in some settings that pose 
greater risks for lawsuits (such as a neurosurgery, high-risk obstetrics, etc.). This may partially 
explain the disparity between ARNP malpractice rates and physician malpractice rates.  
  There are 34 states that allow ARNPs full controlled substance prescriptive authority. In 
states where ARNPs are allowed to fully prescribe, physicians had no significant difference in 
malpractice claims as compared to physicians in states where ARNPs are not allowed to fully 
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prescribe. This is significant in that the Florida state legislature has had concerns that ARNPs 
who were able to fully prescribe controlled substances would increase the supervising 
physician’s malpractice rates. This study does not support that finding. In the fifteen states that 
allow ARNPs partial controlled substance prescriptive authority, the findings again concurred 
that there was no increase in physician malpractice rates. ARNPs in states with partial controlled 
substance prescriptive authority had the lowest malpractice rates overall (4.48/1000 ARNPs), but 
not significantly different from ARNPs in states with full prescriptive authority (7.00/1000 
ARNPs) or the national mean (6.29/1000 ARNPs).  This is noteworthy in that it appears that 
increasing the scope of practice by allowing ARNPs to prescribe controlled substances will not 
likely increase the supervising physician’s liability, nor the ARNPs liability.   
  In reviewing the two states that do not have any level of controlled substance 
prescribing, the malpractice rate for physicians and ARNPs are higher than in states with partial 
or full controlled substance prescriptive authority, although not significantly. One possible 
explanation for the higher malpractice rates are the state rules surrounding controlled substance 
prescribing. For example, ARNPs who do not have the ability to write for a controlled substance 
when one is clearly indicated potentially can be accused of delay of care, or inappropriate 
treatment because the most appropriate medication cannot be prescribed. If the physician is not 
at the site of service, the patient is frequently asked to secure another appointment to see the 
physician so that they can evaluate the patient and prescribe the medication. In this situation, 
care has been delayed.  
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The disparity of the number of states with full prescribing (34), partial prescribing (15) 
and no controlled substance prescribing (2) may have abnormally skewed the data. Florida 
ARNPs alone had more malpractice claim reports (M = 14.24) than any other state, and twice the 
number as the next highest state (Texas M = 8.47). There is no data base available which looks 
specifically at malpractice claims related to controlled substance prescribing. What can be shown 
is that ARNPs who have the authority to prescribe controlled substances show no greater 
preponderance for having a lawsuit brought against them than ARNPs without controlled 
substance prescribing.  
 To provide a comparison to the NPDB information, data was also gathered from the 
HIPDB. In comparing the three groups of states, those with full, partial and no controlled 
substance prescriptive authority, ARNPs in those states with no controlled substance prescribing 
had considerably more adverse actions, civil judgments, and criminal convictions than ARNPs in 
states with partial or full controlled substance prescriptive authority. Specifically, however, 
Alabama had the greatest number of HIPDB reports (175) compared to Florida (42). Florida’s 
individual number of HIPDB reports was not much different from other states regardless of 
prescribing privileges. In evaluating physician adverse actions, criminal convictions and civil 
judgments, there were no significant differences throughout the United States, regardless of 
ARNP prescribing authority.  
 As noted above, there are several factors which could contribute to malpractice rates. The 
final evaluation was to see if states that were demographically similar to Florida had similar 
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malpractice rates. Three states were chosen that most closely matched Florida in terms of total 
state resident population and number of persons uninsured. States that were demographically 
similar included Illinois, New York and Texas with Illinois and Texas allowing partial 
prescriptive authority and New York allowing full prescriptive authority. The results show that 
malpractice rates for ARNPs remain appreciably lower in states demographically similar to 
Florida even when allowed partial or full prescriptive authority.  
 There are several limitations to this study and the interpretation of the data.  The National 
Practitioner Data Bank requires mandatory reporting for MDs and DOs but voluntary reporting 
for ARNPs. This could lessen the accuracy of the data. In addition, there is no data set available 
which looks specifically at malpractice claims related to controlled substance prescribing. 
Developing a monitoring tool to track malpractice claims as they are related to controlled 
substance prescribing would provide the State of Florida with accurate information regarding the 
nature of the malpractice (inappropriate dose prescribed, adverse outcome, drug trafficking, etc) 
and provide information to use to address inappropriate prescribing.  
 In conclusion, there are currently 48 states and the District of Columbia that allow some 
form of controlled substance prescribing. No state has ever rescinded a law granting ARNP 
controlled substance prescribing. There have been many studies which show that ARNPs provide 
care comparable to physicians, and that overall, ARNPs prescribe less medications than 
physicians (Haider, 2008, Horrocks, 2002; Brown and Grimes, 1995). In December, 2008, the 
Florida Senate’s Committee on Health Regulation was given a recommendation based on 
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extensive study to grant controlled substance prescribing authority to Florida licensed ARNPs 
who have attained national certification.  One senator again brought up the safety of ARNPs 
prescribing controlled substances and directly asked about malpractice rates in other states that 
allow ARNPs this authority. This study showed that there is no increase in malpractice rates, 
adverse actions, criminal convictions or civil judgments in states where ARNPs prescribe 
controlled substances, either fully or partially, supporting the hypothesis. In fact, states that do 
not have controlled substance prescriptive authority have increased malpractice rates or 
increased criminal convictions, civil judgments, and adverse actions than states that do not.  
 There are two implications for this study. This study has implications for nursing practice 
in that ARNPs who are allowed to prescribe fully can provide comprehensive, cost-effective care 
(Kaplan & Brown, 2004). Patients who can be treated fully by ARNPs spend less time in the 
office and have less return visits to have their needed prescriptions (Chandler, 2007). This study 
also shows the need for a comprehensive data base that tracks specifically controlled substance 
errors. There are other tracking systems including the Health Integrity Protection Data Bank, and 
this does delineate medication errors, but does not separate RN medication errors from ARNP 
prescribing errors. In addition, national requirements for mandatory reporting to the National 
Practitioner Data Bank for all providers would help to provide more accurate data.  
 Recommendations for future studies would include a concurrent study in a controlled 
setting, such as a healthcare facility, to monitor ARNP and physician controlled substance 
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prescribing errors to compare to the national NPDB rates. This would provide more accurate data 
of the state of controlled substance prescribing errors.  
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NOT HUMAN RESEARCH DETERMINATION 
 
From  :   UCF Institutional Review Board #1 
          FWA00000351, IRB00001138 
 
To      :   Deborah C. Chandler, ARNP  
 
Date   :  February 4, 2010  
 
Dear Researcher: 
 
Thank you for sending the description of your proposed research to the IRB office.  After reviewing this 
information and discussing your plans on the phone, the IRB determined that the following proposed 
activity is not human research as defined by DHHS regulations at 45 CFR 46 or FDA regulations at 21 
CFR 50/56: 
 
Type of Review: Not Human Research Determination 
Project: Analysis of nurse practitioner and physician 
malpractice in all fifty states – publically available 
data, as well as previously published in medical 
journals; no personal identifiers. 
Investigator: Deborah Chandler 
Research ID:   N/A 
  
University of Central Florida IRB review and approval is not required. This determination applies only to 
the activities described in the IRB submission and does not apply should any changes be made. If changes 
are to be made and there are questions about whether these activities are research involving human 
subjects, please contact the IRB office to discuss the proposed changes. 
 
On behalf of the IRB Chair, Joseph Bielitzki, DVM, this letter is signed by: 
 
Joanne Muratori 
IRB Coordinator 
 
cc:  Dr. Elizabeth Rash 
  
University of Central Florida Institutional 
Review Board 
Office of Research & Commercialization 
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